PT - JOURNAL ARTICLE AU - Pagani, Gabriele AU - Conti, Federico AU - Giacomelli, Andrea AU - Bernacchia, Dario AU - Rondanin, Rossana AU - Prina, Andrea AU - Scolari, Vittore AU - Gandolfi, Cecilia Eugenia AU - Castaldi, Silvana AU - Marano, Giuseppe AU - Ottomano, Cosimo AU - Boracchi, Patrizia AU - Biganzoli, Elia AU - Galli, Massimo TI - Seroprevalence of SARS-CoV-2 significantly varies with age: preliminary results from a mass population screening AID - 10.1101/2020.06.24.20138875 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.24.20138875 4099 - http://medrxiv.org/content/early/2020/08/28/2020.06.24.20138875.short 4100 - http://medrxiv.org/content/early/2020/08/28/2020.06.24.20138875.full AB - Objectives Castiglione D’Adda is one of the municipalities more precociously and severely affected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) epidemic in Lombardy. With our study we aimed to understand the diffusion of the infection by mass seroprevalence screening.Methods We searched for SARS-CoV-2 IgGs in the entire voluntary population using lateral flow immune-cromatographic tests on capillary blood (rapid tests). We then performed chemioluminescent serological assays (CLIA) and naso-pharyngeal swabs in a randomized representative sample of 562 subjects and in every subject with a positive rapid test.Results Based on CLIA serologies on the representative random sample (509 subjects), we estimated a 23% IgG seroprevalence. We also found a strong correlation between age and prevalence, with the elderly showing the highest probability of a positive serological test.Conclusions In an area of unrestricted viral circulation less than one-fourth of the population tested positive for SARS-CoV-2 IgG. Seroprevalence increased with increasing age, possibly suggesting differences in susceptibility to the infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the non-conditioning economical support from CISOM (Corpo Italiano di Soccorso dell'Ordine di Malta), Banca Mediolanum s.p.a., Fondazione Rava and FC Internazionale Milano.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by University of Milan's Ethical Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesComplete dataset is available on a reasonable request.